Study of NAT1 and NAT2 Genes in Colorectal Cancer and Inflammatory Bowel Disease
Author Information
Author(s): Mahid Suhal S, Colliver Daniel W, Crawford Nigel PS, Martini Benjamin D, Doll Mark A, Hein David W, Cobbs Gary A, Petras Robert E, Galandiuk Susan
Primary Institution: University of Louisville School of Medicine
Hypothesis
NAT1 and/or NAT2 polymorphisms contribute to the increased cancer evident in inflammatory bowel disease.
Conclusion
This study did not demonstrate an association between NAT1 and NAT2 polymorphisms and inflammatory bowel disease or sporadic colorectal cancer.
Supporting Evidence
- The study included a large sample size of 729 participants.
- No significant differences were found in genotype or allele frequencies among the groups.
- Power calculations indicated sufficient sample size to detect differences in frequency.
Takeaway
The study looked at genes that might affect cancer risk in people with bowel diseases, but found no link between those genes and cancer.
Methodology
A case control study with genotyping of NAT1 and NAT2 in 729 Caucasian participants.
Limitations
The study was limited to Caucasian participants, which may affect the generalizability of the results.
Participant Demographics
729 Caucasian participants, including 123 with sporadic colorectal cancer, 201 with Crohn's disease, 167 with ulcerative colitis, 15 with IBD dysplasia/cancer, and 223 controls.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website